Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially ...
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
Better short-term survival with apalutamide versus darolutamide, but lots of unanswered qu ...
If you’re dealing with advanced prostate cancer, the thought of surgery might feel like a lot to take in — and that’s completely understandable. For many men facing an advanced diagnosis, surgery will ...
Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug ...
Breakthrough for prostate cancer patients as NHS now offers life-extending drug - The new medication is suitable for patients who are unable to receive chemotherapy or standard treatments ...
From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...
A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...
As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...
—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...
SAN ANTONIO — A small pilot study delivered a big message about the use of testosterone in men with advanced or metastatic prostate cancer, according to a "Best Abstract" presented at the Sexual ...
Of all the health conditions facing men as they get older, there is no doubt that prostate cancer is the most widely ...